Cryo-Cell Announces Strategic Partnership with S-Evans Biosciences
News Aug 12, 2009
Cryo-Cell International, Inc. has announced that it has signed an exclusive license agreement with S-Evans Biosciences, Inc. (SEB), a privately-held stem cell and genomics technology company located near Shanghai in Hangzhou, Zhejiang Province, People's Republic of China.
The partnership will allow S-Evans Biosciences to market and manufacture proprietary C'elle(SM) menstrual stem cell technology including the processing and storage of menstrual stem cells (MenSCs) exclusively throughout mainland China.
It will also allow SEB to conduct scientific research studies using Cryo-Cell's proprietary C'elle(SM) menstrual stem technology to identify future potential therapeutic applications for a broad possible range of diseases that may affect millions of people. The exclusive license agreement with SEB will provide Cryo-Cell with future royalty fees from the processing and annual storage of menstrual stem cells.
In addition to SEB's business plans to market and manufacture C'elle menstrual stem cells collected from women across mainland China, the company expects to offer other products and services associated with stem cell therapy; gene testing and disease diagnosis. SEB expects to receive funding from private agencies and the government for stem cell research.
In recent years, China has increased its efforts in the field of stem cell research and practice. Currently, scientific research in the country primarily utilizes bone marrow and embryonic stem cells. Clinical applications of stem cells to treat conditions such as acute heart failure, acute liver failure and lower limb ischemia have been reported by many hospitals.
A developing country with the largest population in the world, China's estimated total population is 1.3 billion of which women account for about half. SEB believes that the future market opportunity for the C'elle service in China is potentially significant.
"Stem cell research and development is well-recognized and fast-emerging in China. SEB believes that the innovative proprietary technology of C'elle may provide women with the novel opportunity to collect and cryopreserve their own stem cells that have demonstrated considerable potential to be used in future therapies and are easily harvest from a non-controversial source," stated Dr. Charlie Xiang, CEO of S-Evans Biosciences.
"Through SEB's expansive educational, scientific and medical affiliations, we anticipate that there may possibly be enormous potential opportunity to successfully market the compelling and highly differentiated quality service of C'elle. We are also eager to explore prospective opportunities with Cryo-Cell to collaborate on research and development of future potential stem cell therapies that may utilize this breakthrough technology."
"We are particularly interested in supporting research on stem cells and genomics that may contribute a great deal to improve our life quality and human health", added by Mr. Guojian Shen, chairman of the Pele Group that invested in S-Evans Biosciences.
The strategic partnership between Cryo-Cell International and S-Evans Biosciences comes at an excellent time for healthcare in China. The Chinese government has announced a new healthcare reform plan that is expected to allocate considerable resources towards stem cell research and development. The government also considers women's health an area of priority and has continued to support expansion and improvement of women's healthcare services and institutes throughout the country.
Cell Technology Used to Treat Osteochondral Knee DefectNews
Autologous cells of stromal vascular fraction were transplanted to a 36-year-old man with the use of fibrin matrix.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE